The effectiveness of natural and synthetic immunomodulators in the treatment of inflammatory bowel disease in dogs.
The aim of the study was to evaluate the usefulness of immunomodulators in the treatment of inflammatory bowel disease (IBD) in dogs. Twenty-eight dogs diagnosed with IBD took part in the study. The animals received a food containing extruded immunomodulators: β-1,3/1,6-D-glucan, β-hydroxy-β-methyl-butyrate (HMB) and levamisole for 42 days. Whole blood samples were analysed before and after therapy assessing changes in phagocyte activity (respiratory burst activity, RBA and potential killing activity, PKA), evaluation of proliferation response of mitogen-stimulated lymphocytes and serum gamma globulin levels, lysozyme activity, ceruloplasmin levels and interleukin activity (IL-6 and IL-10). In this experiment, β-1,3/1,6-D-glucan delivered the highest level of treatment efficacy by producing the quickest therapeutic effect, lowering Canine Inflammatory Bowel Disease Activity Index (CIBDAI) values to below 3, improving histopathological parameters, decreasing IL-6 levels, increasing IL-10 concentrations, and producing remission periods longer than six months. HMB and levamisole were also effective in lowering CIBDAI scores, but the abatement of clinical symptoms was slower and less pronounced in comparison with β-1,3/1,6-D-glucan. The results indicate that β-1,3/1,6-D-glucan can be useful in the treatment of canine IBD.
University of Warmia and Mazury in Olsztyn Department of Clinical Diagnostics, Faculty of Veterinary Medicine Oczapowskiego 14 10-957 Olsztyn Poland.
Andrzej
A
Rychlik
Renata
R
Nieradka
Małgorzata
M
Kander
Marcin
M
Nowicki
Michał
M
Wdowiak
Anna
A
Kołodziejska-Sawerska
D000276:Adjuvants, Immunologic; D000818:Animals; D004283:Dog Diseases; D004285:Dogs; D007155:Immunologic Factors; D015212:Inflammatory Bowel Diseases; D016753:Interleukin-10
D000276:Adjuvants, Immunologic; D007155:Immunologic Factors; D016753:Interleukin-10